Nasdaq

Zealand Pharma Announces U.S. Commercial Availability of ZEGALOGUE® (dasiglucagon) injection

Copenhagen, DK and Boston, MA, U.S. June 24, 2021 – Zealand Pharma A/S (Nasdaq: ZEAL) (CVR-no. 20045078) a biotechnology company focused on the discovery, development and commercialization of ...
Nasdaq

Zealand Pharma receives first FDA approval and prepares for launch of Zegalogue® (dasiglucagon) injection

There is no change from the financial guidance issued on March 11, 2021. Net product revenue from the sales of commercial products is expected to be DKK 220 million +/- 10%. In 2021, Zealand Pharma ...
Healio

FDA approves rescue pen for treating severe hypoglycemia

Please provide your email address to receive an email when new articles are posted on . The approval of Zegalogue injection 0.6 mg (Zealand Pharma) is based on results from three trials with children ...